Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.
According to a new guideline released by the American College of Rheumatology and American Association of Hip and Knee Surgeons, the risk of joint infection resulting from total hip and knee replacements can be reduced with careful management of anti-rheumatic medications during the perioperative process.
Up to 75 percent of patients with systemic lupus erythematosus -- an incurable autoimmune disease commonly known as lupus -- experience neuropsychiatric symptoms.
Researchers in France have developed a new method that will allow doctors to detect minute amounts of a protein called interferon-a in patient samples.
The fact that men are overrepresented in psoriasis registers and consume more psoriasis care have long led researchers to believe that the common skin disease disproportionally affects men.
Lupus, a chronic autoimmune disease, has proved difficult to treat, but a new international study co-led by a Rush University Medical Center researcher suggests that a drug starting through the pipeline could ameliorate or even eliminate the symptoms in most sufferers.
Using red blood cells modified to carry disease-specific antigens, scientists in the laboratories of Hidde Ploegh and Harvey Lodish have prevented and alleviated two autoimmune diseases—multiple sclerosis (MS) and type 1 diabetes—in early stage mouse models.
New research findings published in the Journal of Leukocyte Biology, suggest that synovial CD4+ T cells that produce IL-21 contribute to joint inflammation by activating synovial fibroblasts in rheumatoid arthritis patients.
A Japanese research group has discovered that a newly-identified autoimmune endocrine disease that leads to hypopituitarism is caused by thymomas (a type of tumor originating from the thymic gland).
Only one new drug has become available over the past 50 years for the estimated 1.5 million Americans and five million-plus people worldwide suffering from lupus, but new research has identified a previously unknown mechanism involved in the immune response that could provide an alternative therapy target.
Investigators at the Medical University of South Carolina report pre-clinical research showing that a genetic variant encoded in neutrophil cystolic factor 1 (NCF1) is associated with increased risk for autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and Sjögren's syndrome, in the January 2017 issue of Nature Genetics.
Results of preclinical studies by investigators at the Medical University of South Carolina reported in the August 2016 issue of Arthritis & Rheumatology demonstrate for the first time that including novel biomarkers in lupus nephritis (LN) prognostic models significantly increases their power to predict therapeutic efficacy.
Non-Europeans have a higher frequency of the gene variants that increase the risk of lupus as compared to the European population, a new study from researchers at the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' and King's College London, has confirmed.
Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses.
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs. SLE severity is highly variable, and this variability is known to be partially dependent on ancestral background.
The results of a study presented today at the European League Against Rheumatism Annual Congress showed for the first time an association between a specific genetic pathway and the development of mouth ulcers in patients with Systemic Lupus Erythematosus (SLE).
The results of a study presented today at the European League Against Rheumatism Annual Congress found a doubled risk of pre-malignant cervical changes, and potentially also an increased risk of cervical cancer, among women with Systemic Lupus Erythematosus (SLE) compared to the general female population.
The results of a study presented today at the European League Against Rheumatism Annual Congress show for the first time that an individual's exposure to air pollution may have a direct role in triggering disease activity as well as airway inflammation in children and adolescents with Systemic Lupus Erythematosus (SLE).
Researchers at Beth Israel Deaconess Medical Center have identified an enzyme that is significantly elevated in mouse models of systemic lupus erythematosus and in blood samples of patients with lupus.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organ systems. Autoantibodies, which are produced by B cells, contribute to development of SLE.